Heron Therapeutics Reschedules Second Quarter 2025 Earnings Release and Conference Call to Friday, August 8, 2025
Heron Therapeutics (Nasdaq: HRTX) has rescheduled its second quarter 2025 financial results release and conference call to Friday, August 8, 2025, at 8:30 a.m. ET, moved up from the previously scheduled date of August 11, 2025.
The company will discuss Q2 2025 financial results and recent business highlights during the call. Participants are encouraged to dial in fifteen minutes before the start time using the provided registration link. The presentation will also be available via webcast on Heron's website, with a replay accessible for 60 days following the call.
Heron Therapeutics (Nasdaq: HRTX) ha anticipato la pubblicazione dei risultati finanziari del secondo trimestre 2025 e la conference call al venerd矛 8 agosto 2025, alle 8:30 ET, rispetto alla data precedentemente fissata per l'11 agosto 2025.
Durante la chiamata, l'azienda discuter脿 i risultati finanziari del Q2 2025 e gli ultimi sviluppi aziendali. Si consiglia ai partecipanti di collegarsi quindici minuti prima dell'inizio utilizzando il link di registrazione fornito. La presentazione sar脿 inoltre disponibile in webcast sul sito di Heron, con la possibilit脿 di rivederla per 60 giorni dopo la chiamata.
Heron Therapeutics (Nasdaq: HRTX) ha adelantado la publicaci贸n de los resultados financieros del segundo trimestre de 2025 y la conferencia telef贸nica al viernes 8 de agosto de 2025 a las 8:30 a.m. ET, en lugar de la fecha previamente programada para el 11 de agosto de 2025.
Durante la llamada, la compa帽铆a discutir谩 los resultados financieros del segundo trimestre de 2025 y los recientes aspectos destacados del negocio. Se recomienda a los participantes que se conecten quince minutos antes del inicio utilizando el enlace de registro proporcionado. La presentaci贸n tambi茅n estar谩 disponible por webcast en el sitio web de Heron, con una repetici贸n accesible durante 60 d铆as despu茅s de la llamada.
Heron Therapeutics (雮橃姢雼�: HRTX)電� 2025雲� 2攵勱赴 鞛鞁れ爜 氚滍憸 氚� 旎嵓霟办姢 旖滌潉 旮办〈 鞓堨爼鞚检澑 2025雲� 8鞗� 11鞚检棎靹� 2025雲� 8鞗� 8鞚� 旮堨殧鞚� 鞓れ爠 8鞁� 30攵�(霃欕秬 鞁滉皠)鞙茧 鞎炿嫻瓴检姷雼堧嫟.
鞚措矆 旖滌棎靹滊姅 2025雲� 2攵勱赴 鞛鞁れ爜瓿� 斓滉芳 靷梾 欤检殧 雮挫毄鞚� 雲检潣頃� 鞓堨爼鞛呺媹雼�. 彀戈皜鞛愲摛鞚� 鞝滉车霅� 霌彪 毵來伂毳� 韱淀暣 鞁滌瀾 15攵� 鞝勳棎 鞝戩啀頃� 瓴冹潉 甓岇灔頃╇媹雼�. 氚滍憸 雮挫毄鞚� Heron 鞗轨偓鞚错姼毳� 韱淀暣 鞗轨簮鞀ろ姼搿滊弰 鞝滉车霅橂┌, 旖� 頉� 60鞚缄皠 雼れ嫓氤搓赴 臧�電ロ暕雼堧嫟.
Heron Therapeutics (Nasdaq : HRTX) a avanc茅 la publication de ses r茅sultats financiers du deuxi猫me trimestre 2025 et la conf茅rence t茅l茅phonique au vendredi 8 ao没t 2025 脿 8h30 ET, au lieu de la date initialement pr茅vue du 11 ao没t 2025.
Lors de l'appel, la soci茅t茅 discutera des r茅sultats financiers du T2 2025 ainsi que des faits marquants r茅cents. Les participants sont invit茅s 脿 se connecter quinze minutes avant le d茅but via le lien d'inscription fourni. La pr茅sentation sera 茅galement disponible en webcast sur le site de Heron, avec un replay accessible pendant 60 jours apr猫s l'appel.
Heron Therapeutics (Nasdaq: HRTX) hat die Ver枚ffentlichung der Finanzergebnisse f眉r das zweite Quartal 2025 und die Telefonkonferenz auf Freitag, den 8. August 2025, um 8:30 Uhr ET vorverlegt, urspr眉nglich war der 11. August 2025 geplant.
Das Unternehmen wird w盲hrend des Calls die Finanzergebnisse des zweiten Quartals 2025 sowie aktuelle Gesch盲ftshighlights besprechen. Die Teilnehmer werden gebeten, sich f眉nfzehn Minuten vor Beginn 眉ber den bereitgestellten Registrierungslink einzuw盲hlen. Die Pr盲sentation wird auch per Webcast auf der Heron-Website verf眉gbar sein, mit einer Wiedergabe, die 60 Tage nach dem Call abrufbar ist.
- None.
- None.
The conference call can be accessed by phone by utilizing the following聽聽which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron's website at聽www.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.
About Heron Therapeutics, Inc.
Heron Therapeutics, Inc.聽is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visit聽.
Forward-looking Statements
This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.
Investor Relations and Media Contact:
Ira Duarte
Executive Vice President, Chief Financial Officer
Heron Therapeutics, Inc.
[email protected]
858-251-4400
View original content to download multimedia:
SOURCE Heron Therapeutics, Inc.
FAQ
When is Heron Therapeutics (HRTX) reporting Q2 2025 earnings?
How can investors access Heron Therapeutics' Q2 2025 earnings call?
How long will the replay of Heron Therapeutics' Q2 2025 earnings call be available?
Why did Heron Therapeutics reschedule its Q2 2025 earnings call?
